Dr. Simberg earned his Ph.D. in Biochemistry from the Hebrew University of Jerusalem, Israel. His thesis research focused on the biochemical and biophysical mechanisms of lipofection using cationic lipids. He then conducted postdoctoral research on tumor targeting of iron oxide nanoparticles at the Burnham Institute in La Jolla, California. In 2013, Dr. Simberg joined the faculty of the Skaggs School of Pharmacy at the University of Colorado, where he currently serves as a tenured Professor of Nanomedicine and Nanosafety. Dr. Simberg has authored or co-authored over 90 research papers, reviews, perspectives, and book chapters and has received funding exceeding $12M. His research interests include the development of nanoparticles and cells for drug delivery and imaging, understanding mechanisms of immune recognition of nanomedicines, and understanding mechanisms of drug carrier accumulation in tumors and healthy tissues.
Disclosure information not submitted.
The Upside and Downside of PEGylation and the Emerging Alternatives
Wednesday, July 10, 2024
9:00 AM – 11:00 AM CET
